Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a pioneering company in the field of drug delivery technology. The company has developed and patented a unique drug delivery platform known as DehydraTECH™, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. This technology is notable for significantly improving bio-absorption rates, reducing the onset time of drugs, and masking unpleasant tastes.
DehydraTECH™ has demonstrated remarkable efficacy in enhancing the bio-absorption of cannabinoids and nicotine, increasing their uptake by 5-10 times, and in some cases, by as much as 27 times compared to traditional formulations. This technology also shows potential in improving the delivery of certain drugs through the blood-brain barrier, making it particularly valuable for drugs targeting the central nervous system.
The company operates four key segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. Intellectual Property Licensing is the primary revenue generator for Lexaria, leveraging its robust portfolio of 43 granted patents and numerous pending patents worldwide.
Lexaria's recent endeavors include a series of human and animal studies focused on the application of DehydraTECH™ in enhancing the delivery and efficacy of GLP-1 drugs. These drugs, such as semaglutide and tirzepatide, are primarily used for treating diabetes and promoting weight loss. The company has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics and performance of DehydraTECH-processed GLP-1 drugs.
The latest human pilot studies have shown promising results, including higher drug delivery and better blood glucose control with fewer side effects. The company is also exploring the use of DehydraTECH™ for other APIs like cannabidiol (CBD), with applications in treating hypertension and epilepsy.
Recent financial activities include a warrant exercise agreement, raising approximately $4.7 million, which bolsters Lexaria's operational runway into 2025. This financial stability allows the company to pursue its aggressive research and development plans.
Lexaria's innovative approach and continuous research efforts position it as a significant player in the drug delivery technology sector, with the potential to form strategic partnerships with leading pharmaceutical companies.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces final 12-week results from its diabetes animal study WEIGHT-A24-1. All groups using DehydraTECH technology outperformed Rybelsus® in body weight control. DehydraTECH-liraglutide and DehydraTECH-CBD were top performers, surpassing Rybelsus® control group in body weight-loss by 11.53% and 10.65% respectively, and in blood sugar control by 11.13% and 3.35% respectively. The study maintained diabetic conditions by providing unlimited food and water to animals. DehydraTECH-semaglutide compositions, both with and without SNAC technology, showed superior weight control compared to placebo and standard of care groups.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has contracted a research organization to conduct the first-ever fluorescently tagged DehydraTECH-semaglutide (FTS) rodent biodistribution study. The study will compare two formulations: one mimicking Rybelsus® and another using Lexaria's DehydraTECH processing. The research aims to track how semaglutide distributes in the body using fluorescent imaging in Sprague-Dawley rats, examining tissues including brain, pancreas, lung, kidney, liver, and heart. The study will also evaluate GLP-1 receptor binding patterns using immunofluorescence methodology. Results are expected in May 2025.
Lexaria Bioscience (Nasdaq:LEXX) has received lead clinical site human research ethics committee approval for its Phase 1b, 12-week chronic study GLP-1-H24-4 in diabetes and weight loss. The study will include five arms testing different DehydraTECH formulations: CBD capsules, semaglutide capsules, semaglutide combined with CBD capsules, Rybelsus tablets as control, and tirzepatide capsules as an optional arm. Clinical test article manufacturing for all study arms has been completed. First Patient, First Dose could begin in late December or January 2025. The study will be conducted across seven clinical sites in Australia and is expected to be recognized as a registrational Phase 1b study by the FDA.
Lexaria Bioscience Corp (NASDAQ:LEXX) provides an update on the GLP-1 industry and its strategic positioning. The company is developing its DehydraTECH™ drug delivery platform for application in the GLP-1 space, aiming to position it as essential technology for pharmaceutical companies. The GLP-1 sector has seen significant M&A activity, with major pharmaceutical companies like Novo Nordisk and Eli Lilly making substantial investments. Recent deals include Novo's $285 million license agreement with Ascendis Pharma, a $600 million collaboration with NanoVation Therapeutics, and the $1.08 billion acquisition of Inversago Pharma. The sector is projected to generate between $100 billion to $471 billion in annual revenue.
Lexaria Bioscience (NASDAQ:LEXX) announces partial 12-week blood sugar results from their animal study WEIGHT-A24-1. The study evaluated DehydraTECH-processed formulations of CBD, liraglutide, semaglutide, and Rybelsus. Among eight study groups, DehydraTECH-liraglutide (Group H) showed the most significant reduction in blood sugar levels (-11.54%), followed by DehydraTECH-CBD Group B (-3.76%). This marks the first-ever evaluation of DehydraTECH-processed liraglutide, with notably strong performance compared to other groups. Additional data, including body weight, blood glucose findings, and pharmacokinetic results, are pending from third-party laboratories.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has released partial 12-week body weight results from its animal study WEIGHT-A24-1. The study evaluated various DehydraTECH formulations, including CBD and GLP-1 drugs. Key findings include:
1. DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top-performing weight loss groups.
2. All DehydraTECH groups experienced accelerated rates of weight loss during the final 4 weeks of the study.
3. DehydraTECH-liraglutide outperformed DehydraTECH-semaglutide, which is notable given semaglutide's typically higher effectiveness in humans.
4. Lexaria has filed patent applications for the unique performance of liraglutide processed with DehydraTECH.
The company awaits additional data, including blood glucose findings and pharmacokinetic results.
Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) has closed a $5 million registered direct offering priced at-the-market under Nasdaq rules. The offering included the sale of 1,633,987 shares of common stock at $3.06 per share. Additionally, the company issued unregistered warrants to purchase up to 4,551,019 shares at an exercise price of $3.06 per share in a concurrent private placement.
The warrants will be exercisable after stockholder approval and expire five years from that date. H.C. Wainwright & Co. acted as the exclusive placement agent. Lexaria plans to use the net proceeds for working capital and general corporate purposes. The offering was made under a shelf registration statement, and a final prospectus supplement was filed with the SEC.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced a $5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 1,633,987 shares of common stock at $3.06 per share. Additionally, Lexaria will issue unregistered warrants to purchase up to 4,551,019 shares at the same price in a concurrent private placement.
The warrants will be exercisable after stockholder approval and expire five years later. H.C. Wainwright & Co. is the exclusive placement agent. The offering is expected to close around October 16, 2024. Lexaria plans to use the net proceeds for working capital and general corporate purposes. Upon closing, 2,917,032 outstanding warrants issued in April 2024 will be cancelled.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has initiated dosing for its third human pilot study, investigating an oral dose format of DehydraTECH-processed tirzepatide from Zepbound®. The study involves up to 10 healthy volunteers and consists of two seven-day dosing phases with a multi-week washout period in between. The first phase is set to conclude on October 13, 2024, with the second phase to begin in mid-November. No serious adverse events have been reported. The study will evaluate tolerability, blood absorption levels, and blood sugar control. Tirzepatide, marketed under Zepbound® and Mounjaro® by Eli Lilly™, is expected to generate $15 billion in 2024. Lexaria aims to demonstrate significant absorption rates for oral tirzepatide, building on previous studies showing improved absorption and reduced adverse events for DehydraTECH-processed semaglutide.
Lexaria Bioscience Corp. (NASDAQ:LEXX) provides an update on the rapidly growing GLP-1 receptor agonist market. The market has expanded from less than $4 billion in 2020 to a projected $44.5-$49.3 billion in 2024, with analysts forecasting up to $471.1 billion by 2033. Currently, over 95% of the market is dominated by two drugs: semaglutide and tirzepatide. The oral tablet form of these drugs, which currently comprises only 10% of the market, is expected to grow significantly.
Lexaria's DehydraTECH drug delivery system aims to lead in oral GLP-1/GIP drug delivery. Recent studies have shown GLP-1 drugs' potential in reducing cardiovascular risks and improving outcomes for chronic kidney disease patients, suggesting possible expanded therapeutic applications in the future.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
What is Lexaria Bioscience Corp. known for?
How does DehydraTECH™ improve drug delivery?
What are the main business segments of Lexaria?
What recent achievements has Lexaria accomplished?
What are some key applications of DehydraTECH™?
How many patents does Lexaria hold?
What partnerships has Lexaria recently engaged in?
What financial activities has Lexaria recently undertaken?
How does DehydraTECH™ benefit centrally active compounds?
Where can I find more information about Lexaria?
